Dementia patients want effective drugs. How will the FDA respond?
Dementia patients want effective drugs. Five years ago, the Food and Drug Administration (FDA) proposed changes to speed drug approvals for Alzheimer’s disease (AD). No new drugs have been approved. This year, a new FDA draft guidance discusses considering biomarker data and changing cognitive evaluations for accelerated approvals. Would that help make effective drugs available, or are we lowering our expectations?
Numerous dementia agents have failed current …
Dementia patients want effective drugs. How will the FDA respond?



















